Cell and Gene Therapy Partnering and Deal-Making – Where Now?

One Nucleus is partnering with Taylor Wessing to hold a panel to discuss current trends in cell & gene therapy partnering and deal-making, in particular how these deals differ from those for more traditional modalities.

In this interactive event the panel will share insights on how the unique characteristics of C&GT products and technologies drive different approaches to deal-marking. Topics for the panel will include:

• Due diligence and deal origination – differences from other modalities?
• Interesting recent data from Charles River on pace of deal activity, deal type, deal value and product phase compared to mAB deals;
• How to approach milestones, royalty model and other deal terms?
• Greater focus on manufacturing process development and scale-up, tech transfer and/or clinical supply

Programme:

16.00: Welcome from One Nucleus

16.05: Panel discussion with

Chair: Adrian Toutoungi, Partner at Taylor Wessing

Panellists:

• Conor Johnston, General Counsel, Mogrify
• Michael Bennett – Business Development director, Emerging Therapies, Kyowa Kirin
• Kerstin Papenfuss, early-stage VC, Deep Science Ventures
• Anna Gregson, Partner and Patent Attorney specialising in cell and gene therapies, Mathys & Squire  
• Chris Williams, VP Global Head of Business Development, Autolus

17.00: End

Attend this talk to learn how to put together a successful partnering deal for cell and gene therapy partnering deal and understand what the innovators, big pharma and investors are looking for.

Although there will be opportunity to pose questions on the day, you are invited to submit your questions in advance to Aline, aline@onenucleus.com

Free to attend and open to all